Multivariate predictors of high inhaled corticosteroid dose# at follow-up in patients with adult-onset asthma
| Variable+ | OR | 95% CI | p-value¶ |
| Age at onset >40 years | 3.28 | 0.97–11.04 | 0.056 |
| Male sex | 0.47 | 0.14–1.62 | 0.233 |
| FEV1 post-bronchodilator at diagnosis <80% pred | 4.50 | 1.01–19.98 | 0.048 |
| Waist circumference > 80/94 cm (female/male) at follow-up | 0.48 | 0.12–1.98 | 0.312 |
| FEV1/FVC post <0.75 at follow-up | 3.84 | 1.29–11.40 | 0.015 |
| Every 10 pack–years smoked at follow-up | 1.34 | 0.68–2.64 | 0.396 |
| IL-6 >1.55 pg·mL−1 at follow-up | 3.49 | 1.08–11.29 | 0.037 |
| Blood neutrophils >3.9×109·L−1 at follow-up | 5.91 | 1.85–18.89 | 0.003 |
| Blood eosinophils >0.2×109·L−1 at follow-up | 7.25 | 2.25–23.40 | 0.001 |
| ACT score at follow-up | |||
| 16–20 | 2.12 | 0.55–8.18 | 0.275 |
| 5–15 | 3.18 | 0.50–20.92 | 0.221 |
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACT: asthma control test. Bold indicates significance. #: >800 µg daily dose of budesonide equivalent. ¶: versus patients with 0–400 µg budesonide equivalent in use. +: all factors adjusted for in the final model are shown; also other factors, such as body mass index were tested but excluded from the final analysis because of lower predictive value compared with the factors included (e.g. body mass index versus waist circumference).